Human Longevity Inc., a genomics and cell therapy-based diagnostic and therapeutic company focused on extending the healthy, high performance human life span, called on physicians, the insurance industry and political leaders to support promising new avenues of medical discovery on behalf of patients with life-threatening diseases including cancer. HLI is dedicated to changing the practice of healthcare and to positively impacting aging and age-related diseases using advances in genomics and stem cell therapies. The company is building the largest human genome sequencing operation in the world to compile the most comprehensive human genotype, microbiome, and phenotype database available to tackle the diseases associated with aging-related human biological decline. HLI’s co-founders are: Robert Hariri, stem cell pioneer; J. Craig Venter, biologist and genomics leader; and Peter Diamandis, chairman and CEO of the XPRIZE Foundation.
“Today people with cancer must wage war on two fronts, battling their disease and fighting for advanced treatments,” said Hariri. “The oncology field is changing rapidly. Every tumor is different and every patient is different. HLI believes the time is now to incorporate every individual’s genetic code as the starting point of care and therapeutic development.”
The value of innovation in healthcare is well-documented. A report in the journal, Clinical Cancer Research stated that continued support for science and innovation could avert a predicted crisis in health spending in oncology just as it has in other major public health problems, such as HIV/AIDS.
Hariri, HLI co-founder and the chairman, founder, chief scientific officer, and former chief executive officer of Celgene Cellular Therapeutics, speaks at BIO 2014 in San Diego on how medical innovation in the fields of cancer and stem cell therapeutics can save money and save lives. HLI plans to work closely with the Value of Medial Innovation and in a project called My Life Is Worth It. This new online initiative was launched recently to give patients a voice in discussions about the value of the very treatments that will affect their own lives.
Date: June 25, 2014
Source: Human Longevity
